A Phase II, International Open Label Trial of Minnelide™ in Patients With Refractory Pancreatic Cancer
Status:
Completed
Trial end date:
2019-07-01
Target enrollment:
Participant gender:
Summary
MinPAC aims to see if the drug Minnelide can slow down tumour growth in patients with
pancreatic cancer that is not responding to treatment. Minnelide is designed to rapidly
release the anti-tumour molecule triptolide in the bloodstream and has been shown to slow
cancer cell growth and induce cancer cell death. Minnelide is currently being investigated in
other early phase trials and has shown promising response data.
There are strict eligibility criteria for this trial. Broadly speaking, patients with
pancreatic cancer that has spread to other organs and has progressed on one or more
chemotherapy regimens are eligible. Participants will receive Minnelide on days 1-21 of each
28 day cycle until their cancer stops responding to treatment. After that participants will
be followed up 3 monthly for the collection of disease status and survival data.
MinPAC includes biological and imaging studies. Participants will be asked to donate tumour
and blood samples and will be asked to undergo additional PET Scans. The study is being
carried out in 4 sites in the UK and USA.
Phase:
Phase 2
Details
Lead Sponsor:
Minneamrita Therapeutics LLC Queen Mary University of London
Collaborators:
Barts & The London NHS Trust Cancer Research UK Lustgarten Foundation Minneamrita Therapeutics LLC Queen Mary University of London Stand Up To Cancer Translational Genomics Research Institute